199 related articles for article (PubMed ID: 9314293)
1. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Hortobagyi GN; Holmes FA; Theriault RL; Rahman Z; Buzdar AU
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-13-S11-19. PubMed ID: 9314293
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
3. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Tolcher AW
Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
Sledge GW
Semin Oncol; 1995 Oct; 22(5 Suppl 12):123-5; discussion 126-9. PubMed ID: 7481854
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Hortobagyi GN; Willey J; Rahman Z; Holmes FA; Theriault RL; Buzdar AU
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
Hortobagyi GN; Ibrahim N
Semin Oncol; 1996 Feb; 23(1 Suppl 1):53-7. PubMed ID: 8629039
[TBL] [Abstract][Full Text] [Related]
11. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Kennedy MJ; Donehower RC; Rowinsky EK
Semin Oncol; 1995 Aug; 22(4 Suppl 8):23-7. PubMed ID: 7543700
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Buzdar AU; Holmes FA; Hortobagyi GN
Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Casadei Giunchi D; Gentile A; Salzano E
Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Paridaens R
Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Sledge GW
Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
